Piper Sandler Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by Piper Sandler from $40.00 to $15.00 in a report published on Friday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other research firms also recently commented on KROS. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, Truist Financial dropped their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Trading Up 3.2 %

KROS opened at $10.86 on Friday. The company has a 50 day moving average of $36.37 and a 200 day moving average of $47.16. The company has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) earnings per share. Research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently added to or reduced their stakes in KROS. SG Americas Securities LLC purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at about $388,000. Geode Capital Management LLC grew its position in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after acquiring an additional 46,041 shares during the last quarter. Barclays PLC raised its stake in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after acquiring an additional 35,022 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Keros Therapeutics during the third quarter worth approximately $868,000. Finally, Point72 DIFC Ltd lifted its holdings in shares of Keros Therapeutics by 9.8% in the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after acquiring an additional 1,715 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.